title: Palifermin for management of treatment-induced oral mucositis in cancer patients.
abstract: Oral mucositis (OM) remains a major side effect of various cancer therapies, which exacts a significant price in terms of morbidity and cost of care. Efforts aimed at prevention and/or therapy of OM have been largely unsuccessful. Few agents have shown efficacy, and even those were applicable to limited types of patients. The advent of small-molecule targeted agents opened new possibilities for intervention in the mucopathogenic processes induced by cancer therapies. One of these agents, recombinant human keratinocyte growth factor (KGF), has been studied extensively and has shown promising results in reducing chemotherapy induced OM. This drug's effects on stem cell engraftment, graft-versus-host disease and other treatment-induced morbidities remain undefined. In this article we evaluate the pre-clinical and clinical evidence and discuss the clinical applications of KGF as an adjunct therapeutic agent in oncology.
authors.affiliation: Department of Diagnostic Sciences, University of Alabama at Birmingham, Birmingham, AL, USA. abarasch@uab.edu
authors.forename: Andrei
authors.initials: A
authors.lastname: Barasch
authors.forename: Joel
authors.initials: J
authors.lastname: Epstein
authors.forename: Ken
authors.initials: K
authors.lastname: Tilashalski
references.citation: Nat Rev Cancer. 2004 Apr;4(4):277-84
references.pmid: 15057287
references.citation: Bone Marrow Transplant. 2007 Nov;40(10):983-8
references.pmid: 17846600
references.citation: Cell Prolif. 2002 Aug;35 Suppl 1:86-92
references.pmid: 12139711
references.citation: J Clin Endocrinol Metab. 2003 Feb;88(2):773-80
references.pmid: 12574212
references.citation: N Engl J Med. 2004 Dec 16;351(25):2590-8
references.pmid: 15602019
references.citation: Curr Pharm Des. 2002;8(5):395-403
references.pmid: 12069377
references.citation: J Clin Oncol. 2001 Apr 15;19(8):2201-5
references.pmid: 11304772
references.citation: Cancer Chemother Pharmacol. 2002 Sep;50(3):202-12
references.pmid: 12203102
references.citation: J Clin Oncol. 2008 May 20;26(15):2489-96
references.pmid: 18487568
references.citation: Anticancer Res. 2002 Sep-Oct;22(5):2539-45
references.pmid: 12529961
references.citation: Cancer Res. 1998 Mar 1;58(5):933-9
references.pmid: 9500453
references.citation: Bone Marrow Transplant. 2008 Aug;42(4):275-9
references.pmid: 18500368
references.citation: Biol Blood Marrow Transplant. 2008 Sep;14(9):1017-1021
references.pmid: 18721764
references.citation: Cell Prolif. 2002 Aug;35 Suppl 1:78-85
references.pmid: 12139710
references.citation: J Clin Oncol. 2003 Apr 15;21(8):1452-8
references.pmid: 12697866
references.citation: Support Care Cancer. 2008 May;16(5):477-83
references.pmid: 17710442
references.citation: Cell Prolif. 2002 Aug;35 Suppl 1:32-47
references.pmid: 12139706
references.citation: Int J Radiat Biol. 2001 Mar;77(3):341-7
references.pmid: 11258848
references.citation: Mol Cancer Res. 2008 Aug;6(8):1337-46
references.pmid: 18708365
references.citation: Cell Biol Int. 1995 May;19(5):399-411
references.pmid: 7640656
references.citation: Cancer Chemother Pharmacol. 2002 Jul;50(1):53-8
references.pmid: 12111112
references.citation: J Clin Oncol. 2006 Nov 20;24(33):5194-200
references.pmid: 17075109
references.citation: Support Cancer Ther. 2004 Jul 1;1(4):219-29
references.pmid: 18628146
references.citation: Oral Oncol. 2003 Feb;39(2):91-100
references.pmid: 12509961
references.citation: Blood. 2007 Jul 1;110(1):441-9
references.pmid: 17374737
references.citation: Int J Radiat Biol. 1999 May;75(5):609-20
references.pmid: 10374943
references.citation: PLoS One. 2008 Jun 25;3(6):e2528
references.pmid: 18575591
references.citation: Stem Cells. 2008 Oct;26(10):2595-601
references.pmid: 18669914
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8318-24
references.pmid: 15623608
references.citation: Biol Blood Marrow Transplant. 2007 Jul;13(7):806-13
references.pmid: 17580258
references.citation: Blood. 2000 Dec 15;96(13):4350-6
references.pmid: 11110712
references.citation: Ann Oncol. 2008 Sep;19(9):1644-9
references.pmid: 18453519
references.citation: Eur J Oral Sci. 2003 Feb;111(1):42-50
references.pmid: 12558807
references.citation: Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):177-87
references.pmid: 9422575
references.citation: Support Care Cancer. 2007 Jan;15(1):105-9
references.pmid: 16896881
references.citation: Clin Cancer Res. 2003 Aug 15;9(9):3454-61
references.pmid: 12960137
references.citation: Pharmacol Res. 2002 Aug;46(2):179-83
references.pmid: 12220958
references.citation: Gene Ther. 2002 Aug;9(16):1065-74
references.pmid: 12140734
references.citation: Support Cancer Ther. 2005 Jan 1;2(2):122-7
references.pmid: 18628199